Efficacy of trovafloxacin, a new quinolone antibiotic, in experimental staphylococcal endocarditis due to oxacillin-resistant strains

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 7, 1998, Pages 1837-1841

  Bayer, Arnold S ^a,b,c   Li, Cong ^a   Ing, Michael ^a,d  

^a St John's Cardiovascular Research Center   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULTAMICILLIN; TROVAFLOXACIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL ENDOCARDITIS; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DRUG EFFICACY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION;

EID: 0031807493     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.7.1837     Document Type: Article

References (32)

1. Bayer, A. S., D. Crowell, D. Bradley, J. Yih, and D. C. Norman. 1988. Differential antimicrobial pharmacokinetics and pharmacodynamics in right-sided versus left-sided vegetations in experimental Pseudomonas aeruginosa endocarditis. J. Infect. Dis. 158:355-359.
2. Bayer, A. S., C. Li, E. Kim, and M. Ing. 1996. Efficacy of trovafloxacin (CP-99219) in the therapy of experimental endocarditis due to drug-resistant enterococci, abstr. B2, p. 21. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
3. Bayer, A. S., and D. C. Norman. 1990. Valve-site specific pathogenetic differences between right-sided and left-sided bacterial endocarditis. Chest 98:200-205.
4. Bayer, A. S., D. C. Norman, C. Y. Chiu, and C. Nast. 1989. Pathogenetic effects of neutropenia, monocytopenia and steroid treatment in experimental Pseudomonas endocarditis. Chemotherapy 35:278-288.
5. Bayer, A. S., and J. Tu. 1990. Chemoprophylactic efficacy against experimental endocarditis caused by ß-lactamase-producing, aminoglycoside-resistant enterococci is associated with prolonged serum inhibitory activity. Antimicrob. Agents Chemother. 34:1068-1074.
6. Centers for Disease Control and Prevention. 1997. Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. Morbid. Mortal. Weekly Rep. 46:765-766.
7. Centers for Disease Control and Prevention. 1997. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. Morbid. Mortal Weekly Rep. 46:813-815.
8. Chambers, H. F. 1987. Coagulase-negative staphylococci resistant to ß-lactam antibiotics in vivo produce penicillin-binding protein 2a. Antimicrob. Agents Chemother. 31:1919-1924.
9. Chambers, H. F., G. L. Archer, and M. Matsuhashi. 1989. Low-level methicillin resistance in strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 33:424-428.
10. Chambers, H. F., T. Miller, and M. D. Newman. 1988. Right-sided Staphylococcus aureus endocarditis in intravenous drug addicts: two-week combination therapy. Ann. Intern. Med. 109:619-624.
11. Chambers, H. F., and M. Sachedeva. 1990. Binding of ß-lactam antibiotics to penicillin-binding proteins in methicillinn-resistant Staphylococcus aureus. J. Infect. Dis. 161:1170-1176.
12. Dworkin, R. J., B. L. Lee, M. A. Sande, and H. F. Chambers. 1989. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampin. Lancet ii:1071-1073.
13. Eliopoulos, G. M., K. Klimm, C. T. Eliopoulos, M. J. Ferraro, and R. C. Moellering, Jr. 1993. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob. Agents Chemother. 37:366-370.
14. 18F-labeled trovafloxacin in normal and Escherichia coli-infected rats and rabbits studied with positron emission tomography. Clin. Microbiol. Infect. 3:63-72.
15. Hackbarth, C. J. and H. F. Chambers. 1989. Methicillin-resistant staphylococci: detection methods and treatment of infections. Antimicrob. Agents Chemother. 33:995-999.
16. Heldman, A. W., T. V. Hartert, S. C. Ray, E. G. Daoud, T. E. Kowalski, V. J. Pompili et al. 1996. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am. J. Med. 101:68-76.
17. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-rcsistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136.
18. Hirano, L., and A. S. Baver. 1991. ß-lactam-ß-lactamase-inhibitor combinations are active in experimental endocarditis caused by ß-lactamase-producing oxacillin-resistant staphylococci. Antimicrob. Agents Chemother. 35: 685-690.
19. Ing M. B., L. Baddour, and A. S. Bayer. 1997. Staphylococcal bacteremia and infective endocarditis - pathogenesis, diagnosis and complications, p. 331-354. In G. Archer and K. Crossley (ed.), Staphylococci and staphylococcal diseases. Churchill-Livingstone Publishers, New York, N.Y.
20. Kaatz, G. W., S. M. Seo, J. R. Aeschlimann, H. H. Houlihan, R.-C. Mercier, and M. J. Rybak. 1998. Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 42:254-256.
21. Karchmer, A. W., G. L. Archer, and W. E. Dismukes. 1983. Staphylococcus epidermidis causing prosthetic valve endocarditis - microbiologic and clinical observations as guides to therapy. Ann. Intern. Med. 98:447-455.
22. Kim, Y. S., Q. Liu, L. L. Chow, and M. G. Täuber. 1997. Trovafloxacin in treatment of rabbits with experimental meningitis caused by high-level penicillin-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:1186-1189.
23. Korzeniowski, O., M. A. Sande, and The National Collaborative Endocarditis Study Group. 1982. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. Ann. Intern. Med. 97:496-503.
24. Levine, D. P., B. S. Fromm, and B. R. Reddy. 1991. Slow response to vancomycin or vancomycin plus rifampin in therapy among patients with methicillin-resistant Staphylococcus aureus endocarditis. Ann. Intern. Med. 115:674-680.
25. Massanari, R. M., M. A. Pfaller, D. S. Wakesfield, G. T. Hammons, L. A. McNut, R. E. Woolson, et al. 1988. Implications of acquired oxacillin resistance in the management and control of Staphylococcus aureus infections. J Infect. Dis. 158:702-709.
26. Neu, H. C., and N.-X. Chin. 1994. In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob. Agents Chemother. 38:2615-2622.
27. Piercy, E. A., D. Barbara, J. P. Luby, and P. A. Mackowiak. 1989. Ciprofloxacin for methicillin-resistant Staphylococcus aureus infections. Antimicrob. Agents Chemother. 33:128-130.
28. Pittet, D., and R. P. Wenzel. 1995. Nosocomial blood-stream infections -secular trends in rates, mortality and contribution to total hospital deaths. Arch. Intern. Med. 155:1177-1184.
29. Ramos, M. C., M. Ing, E. Kim, M. D. Witt, and A. S. Bayer. 1996. Ampicillin-sulbactam is effective in prevention and therapy of experimental endocarditis caused by ß-lactam-producing coagulase-negative staphylococci. Antimicrob. Agents Chemother. 40:97-101.
30. Sanders, C. C., W. E. Sanders, Jr., and K. S. Thomson. 1995. Fluoroquinolone-resistance in staphylococci-new challenges. Eur. J. Clin. Microbiol. Infect. Dis. 14(Suppl.):6-11.
31. Sidebottom, D. G., J. Freeman, R. Platt, M. F. Epstein and D. A. Goldmann. 1988. Fifteen-year experience with bloodstream isolates of coagulase-negative staphylococci. J. Clin. Microbiol. 26:713-718.
32. Vincent, J., J. Venitz, R. Teng, B. A. Baris, S. A. Willavize, R. J. Polzer, and H. L. Friedman. 1997. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. J. Antimicrob. Chemother. 39(Suppl.):75-80.